This SafeHeal study is designed to assess the overall safety of the low anterior
resection (LAR) standard of care cancer treatment by establishing a definition of major
complications. The current literature on standard of care reports adverse
events/complications but does not provide a single endpoint that can be used to compare
the safety of LAR cancer treatment to alternative therapies or treatments. This study
will allow for the establishment of a new single safety endpoint for LAR standard of care
cancer treatment.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06152276.
Locations matching your search criteria
United States
Illinois
Chicago
Northwestern UniversityStatus: Active
Name Not Available
This SafeHeal study is designed to assess the overall safety of the low anterior
resection (LAR) standard of care cancer treatment by establishing a definition of major
complications. The current literature on standard of care reports adverse
events/complications but does not provide a single endpoint that can be used to compare
the safety of LAR cancer treatment to alternative therapies or treatments. This study
will allow for the establishment of a new single safety endpoint for LAR standard of care
cancer treatment.
The data from this study could serve as the historical control arm data of a SafeHeal
Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-3) Pivotal Study
designed as a prospective, non-randomized, sequential, controlled, multicenter trial
comparing the investigational device, the next generation Colovac Anastomosis Protection
Device, to the standard of care (SOC), diverting ostomy.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationSafeHeal Inc
Principal InvestigatorMarcos Velez-Duran